DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20222871
Published: 2022-10-28

Immunohistochemical expression of galectin-3 in carcinoma of uterine cervix

Chandershekhar ., Gajender Singh, Monika Dhankher, Zeany Cheran

Abstract


Background: Cervical cancer is one of the most common cancer among women worldwide, second to breast cancer. It’s difficult to diagnose in the early stage due to subtle and non-specific symptoms. Galectin-3 is increasingly being recognized as an important regulator of a broad range of cancer cell activities including cervical cancer. Its expression depends on the tumor grade which signifies its role in progression of the disease and prognostic significance.

Method: The present study was conducted in department of pathology, Pt. B. D. Sharma PGIMS, Rohtak on 60 cases of histo-pathologically diagnosed squamous cell carcinoma of uterine cervix. Immunohistochemical (ICH) expression of marker ‘Galectin-3’was assessed in all biopsy specimens.

Results: Galectin-3 expression was 1+ in 83.3% cases and 2+ in 16.6% cases of grade 1 cervix carcinoma. In grade 2 carcinomas 55.3% showed 1+, 42.1% showed 2+ and 2.6 % cases showed 0 galectin -3 expression. Further, 70% of grade III cases showed a score of 2+, and 10 % showed 1+ expression and 20 % didn’t show any galectin 3 positivity. A statistically significant association of galectin-3 expression with histological grade was observed.

Conclusions: IHC expression of galectin-3 can be used as an important marker for grading of cervical carcinoma, therefore the present study was done to evaluate the IHC expression of galectin 3 in cervical cancer and correlate it with histologic tumour grade.


Keywords


IHC, Galectin 3, Tumor grade

Full Text:

PDF

References


World Health Organization. Cervix cancer: prevention and control. Available at: https://www.who.int/cancer/cervical-cancer. Accessed on 11 September 2019.

Lee JW, Song SY, Choi JJ, Choi CH, Kim TJ, Kim J et al. Decreased galectin-3 expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol. 2006;132:241-7.

World Health Organization. Cervix cancer: prevention and control. Available at: https://www.who.int/cancer/cervical-cancer. Accessed on 11 September 2019.

Cay T. Immunhisto-chemical expression of galectin-3 in cancer: a review of the literature. Türk Patoloji Derg. 2012;28(1):1-10.

Liu J, Cheng Y, He M, Yao S. Vascular endothelial growth factor C enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein. Gynecol Endocrinol. 2014;30(6):461-5.

Jackson P, Blythe D. Immunohistochemical techniques. In: Bancroft JD, Gamble M, editors. Theory and Practice of Histological techniques. 7th ed. New York: Churchill Livingstone. 2012;381-426.

Gamble M. The Hematoxylins and Eosin. In: Bancroft JD, Gamble M. Theory and Practice of Histologic techniques. 6th ed. Philadelphia: Churchill Livingstone. 2008:121-34.

Bio-Medical Waste Management (Amendment) Rules 2018. New Delhi: Gazette of India, Extraordinary, Part II, Section 3, Subsection (i); 2018. Available at: http://www.egazette.nic.in/Write ReadData/2018/183847.pdf. Accessed on 11 Sep, 2019.

Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 2011;313(2):123-8.

Kim SS, Cho HY, Kang SW, Kim HB, Park SO. Is the expression of p16ink4a and galectin‐3correlated with disease progression of cervical neoplasia? Korean J Obstet Gynecol. 2011;54(4):192-8.

Punt S, Thijssen VL, Vrolijk J, de Kroon CD, Gorter A, Jordanova ES. Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer. PLoS ONE. 2019;10(6): e0129119.

Li M, Feng YM, Fang SQ. Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 2017;50(4):e5356.

Ma J, Zhang X, He G, Yang C. The relationship between cervical precancerous lesion galectin-3 and p27 protein expression and clinical prognosis. Oncol Lett. 2018:15:1533-6.

Kumar R, Mandal S, Arora P, Mala YM, Khurana N. The expression of p16 and galectin-3 in cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC) uterine cervix. J Obstet Gynaecol. 2021;41(5):785-90.